RHU

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

Trailblazing California Leaders Celebrated by The James Irvine Foundation for Innovative Leadership

Retrieved on: 
Monday, February 12, 2024

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire-PRWeb/ -- The James Irvine Foundation today announced the recipients of its 2024 Leadership Awards, honoring nine leaders from six organizations for their dedicated efforts in addressing critical issues impacting Californians. This year's Award recipients are an impressive group of innovators working on a wide range of challenges including teacher preparation, youth justice, college access and completion, and ensuring the health and safety of Asian American and Pacific Islander, LGBTQ+, refugee, and immigrant populations.

Key Points: 
  • "The California Way means finding new solutions to big problems, and that's exactly what these leaders have demonstrated through their innovative work."
  • "I thank The James Irvine Foundation for its commitment to lifting up the impactful work of community leaders across our state to build a more vibrant, inclusive and resilient California."
  • "The accomplishments of these diverse leaders and their ongoing commitment to improving the lives of Californians are truly inspiring," said Don Howard, President and CEO of The James Irvine Foundation.
  • Since 2006, The Irvine Foundation has celebrated the achievements of over 100 leaders in California.

Domain Therapeutics Awarded Hospital-University Research in Health (RHU) SPRINT Consortium Grant to Progress Its Proprietary CCR8 Antibody Candidate to the Clinic

Retrieved on: 
Thursday, January 25, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces it has been awarded a grant as part of the Hospital-University Research in Health (RHU) SPRINT consortium.
  • View the full release here: https://www.businesswire.com/news/home/20240125583037/en/
    The SPRINT project aims to revolutionize the management of patients with CTCL and deliver a new cure paradigm as a standard-of-care.
  • The grant that we have been awarded by the RHU SPRINT consortium will support the progress of DT-7012, an anti-CCR8 monoclonal antibody which has incredible potential as a best-in-class therapeutic, into the clinic.
  • Domain was already awarded a first RHU grant, RHU CONDOR for Sarcoma, in the previous campaign, leveraging another proprietary asset.

Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries

Retrieved on: 
Friday, January 19, 2024

Audiogene will also assess the clinical safety, performance, and usability of the administration device system under development in partnership with EVEON.

Key Points: 
  • Audiogene will also assess the clinical safety, performance, and usability of the administration device system under development in partnership with EVEON.
  • The design of the study will consist of two cohorts of 2 doses followed by an expansion cohort at the selected dose.
  • The CTA approval follows extensive preclinical studies assessing the safety and efficacy of SENS-501 and successful manufacturing of the gene therapy Drug Product for the clinical trial.
  • Sensorion presented preclinical data that indicated the potential for safe and efficient clinical translation of gene therapy for otoferlin delivered by a dual AAV vector.

VITABLE HEALTH WELCOMES VANCE SIBLE AS HEAD OF TPA PARTNERSHIPS

Retrieved on: 
Thursday, January 25, 2024

PHILADELPHIA, Jan. 25, 2024 /PRNewswire/ -- Vitable Health , a leading enhanced direct primary care built to reduce claims cost under self-funded groups, is thrilled to announce the appointment of Vance Sible, CSFS, RHU, HIA, as the Head of TPA Partnerships.

Key Points: 
  • PHILADELPHIA, Jan. 25, 2024 /PRNewswire/ -- Vitable Health , a leading enhanced direct primary care built to reduce claims cost under self-funded groups, is thrilled to announce the appointment of Vance Sible, CSFS, RHU, HIA, as the Head of TPA Partnerships.
  • In his new role, Vance will spearhead collaborations with Third-Party Administrators (TPAs), Stop-Loss companies, and Broker partners to help expand the reach of Vitable Health nationwide.
  • Vitable's TPA and Stop-Loss partnerships will deliver active reductions in overall healthcare costs for self-insured employers while providing additional delightful health benefits to their members.
  • Vance Sible brings over 38 years of invaluable experience in the health insurance industry, specializing in senior leadership roles in sales and account management.

AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”

Retrieved on: 
Monday, November 27, 2023

THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".

Key Points: 
  • THE CLINICAL DEVELOPMENT OF MASITINIB IN SICKLE CELL DISEASE, A HIGHLY PREVALENT GENETIC CONDITION, IS AMONG THE 19 WINNING PROJECTS UNDER THE SIXTH CALL FOR "HOSPITAL-UNIVERSITY RESEARCH IN HEALTH (RHU)".
  • A new patent has been filed, which, if granted, will extend the international protection of masitinib in sickle cell disease until 2040.
  • Current treatment options such as hydroxycarbamide, chronic transfusion or anti-P-selectin antibodies, do not fully prevent life-threatening acute and chronic complications of sickle cell disease.
  • There is a significant medical need to prevent the acute and chronic complications of sickle cell disease.

Jenifer McMahon Joins Alliant Insurance Services’ Seattle Benefits Team

Retrieved on: 
Wednesday, June 28, 2023

Jenifer McMahon has joined Alliant Insurance Services as Vice President within its Employee Benefits Group .

Key Points: 
  • Jenifer McMahon has joined Alliant Insurance Services as Vice President within its Employee Benefits Group .
  • In this role, the Seattle-based consultant will provide a full range of strategic benefits solutions to a diverse client base throughout the Pacific Northwest.
  • An experienced health and benefits consultant and relationship manager with decades in the industry, McMahon takes pride in aligning her clients’ organizational objectives and culture with their employee and executive benefits.
  • “Jenifer’s depth of expertise with a wide array of benefits solutions and as a relationship manager will allow her to deliver programs that help her clients thrive in today’s complex benefits environment,” said Kevin Overbey, President, Alliant Employee Benefits.

LIBRA Insurance Partners Names New Board Chairman and Members

Retrieved on: 
Tuesday, June 6, 2023

BALTIMORE, June 6, 2023 /PRNewswire/ -- LIBRA Insurance Partners, the largest independently owned life insurance marketing organization (IMO) in the United States, announces member, Gonzalo M. Garcia, CLU, managing partner of AgencyONE Insurance Marketing Group, LLC as its new chairman of the board. LIBRA also announces the addition of two new board members; Chris Bottaro, MBA, senior vice president of insurance for Valmark Financial Group and Eric Griffin, CLU, RHU, executive vice president of The Carson Group.

Key Points: 
  • BALTIMORE, June 6, 2023 /PRNewswire/ -- LIBRA Insurance Partners, the largest independently owned life insurance marketing organization (IMO) in the United States, announces member, Gonzalo M. Garcia, CLU, managing partner of AgencyONE Insurance Marketing Group, LLC as its new chairman of the board.
  • LIBRA also announces the addition of two new board members; Chris Bottaro, MBA, senior vice president of insurance for Valmark Financial Group and Eric Griffin, CLU, RHU, executive vice president of The Carson Group.
  • "Over the last decade, LIBRA Partners has experienced tremendous growth and I would be remiss if I didn't acknowledge the incredible job Mark Rosen has done serving as our chairman of the board since 2014," said William (Bill) Shelow, CLU®, ChFC®, CPCU®, LLIF, president and CEO of LIBRA.
  • "We are thrilled to welcome Chris and Eric to the board, both of which have demonstrated exemplary leadership skills with their respective organizations.

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

NAIFA Announces Nominees for 2023 National Leadership Positions

Retrieved on: 
Thursday, September 15, 2022

FALLS CHURCH, Va., Sept. 15, 2022 /PRNewswire-PRWeb/ -- The National Association of Insurance and Financial Advisors' (NAIFA's) Committee on Governance has nominated Douglas B. Massey, LUTCF, FSS, Owner of Doug Massey Financial Services in San Angelo, TX, to be the 2023 NAIFA Secretary. A current member of NAIFA's Board of Trustees, Massey has been a loyal NAIFA member since 1987. As incoming Secretary, Massey will be in line to serve as President-Elect in 2024 and President in 2025.

Key Points: 
  • Nominees for Secretary and the Board of Trustees will stand for election later this year at NAIFA's annual business meeting during the National Leadership Conference.
  • The Committee has also nominated two members to serve two-year terms on the NAIFA Board of Trustees.
  • The nominees will stand for election during NAIFA's annual business meeting at the National Leadership Conference (NLC).
  • NAIFA provides producers a national community for advocacy, education and networking along with awards, publications and leadership opportunities to allow NAIFA members to differentiate themselves in the marketplace.